glp 1 egfr cut off GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes Updated evidence on cardiovascular and

This leads to various beneficial effects, including slowed gastric emptying (this is temporarily beneficial, but long-term, this just means constipation is your new normal and SIBO is a possibility), increased satiety, and improved blood sugar control

[1] The SURMOUNT-5 head-to-head trial confirmed Zepbound produces 47% more weight loss than Wegovy (20.2% vs 13.7% at 72 weeks)

Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M

Nonrandomized real-world evidence to support regulatory decision making: process for a randomized trial replication project

Retrieved from Marso, S

GLP-1 helps smooth these spikes and dips by supporting better insulin release and lowering sugar output from the liver